122 related articles for article (PubMed ID: 10536244)
1. Preparation and in vitro characterization of HSA-mPEG nanoparticles.
Lin W; Garnett MC; Schacht E; Davis SS; Illum L
Int J Pharm; 1999 Nov; 189(2):161-70. PubMed ID: 10536244
[TBL] [Abstract][Full Text] [Related]
2. Preparation of surface-modified albumin nanospheres.
Lin W; Garnett MC; Davies MC; Bignotti F; Ferruti P; Davis SS; Illum L
Biomaterials; 1997 Apr; 18(7):559-65. PubMed ID: 9105596
[TBL] [Abstract][Full Text] [Related]
3. Preparation of sterically stabilized human serum albumin nanospheres using a novel Dextranox-MPEG crosslinking agent.
Lin W; Coombes AG; Garnett MC; Davies MC; Schacht E; Davis SS; Illum L
Pharm Res; 1994 Nov; 11(11):1588-92. PubMed ID: 7532861
[TBL] [Abstract][Full Text] [Related]
4. Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method.
Lin W; Coombes AG; Davies MC; Davis SS; Illum L
J Drug Target; 1993; 1(3):237-43. PubMed ID: 8069565
[TBL] [Abstract][Full Text] [Related]
5. Suppression of agglomeration of ciprofloxacin-loaded human serum albumin nanoparticles.
Kumar PV; Jain NK
AAPS PharmSciTech; 2007 Mar; 8(1):17. PubMed ID: 17408217
[TBL] [Abstract][Full Text] [Related]
6. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.
Langer K; Anhorn MG; Steinhauser I; Dreis S; Celebi D; Schrickel N; Faust S; Vogel V
Int J Pharm; 2008 Jan; 347(1-2):109-17. PubMed ID: 17681686
[TBL] [Abstract][Full Text] [Related]
7. PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent.
Fahrländer E; Schelhaas S; Jacobs AH; Langer K
Nanotechnology; 2015 Apr; 26(14):145103. PubMed ID: 25789544
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
Kim I; Kim TH; Ma K; Lee ES; Kim D; Oh KT; Lee DH; Lee KC; Youn YS
Bioconjug Chem; 2010 Aug; 21(8):1513-9. PubMed ID: 20715855
[TBL] [Abstract][Full Text] [Related]
9. A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation.
Wacker M; Zensi A; Kufleitner J; Ruff A; Schütz J; Stockburger T; Marstaller T; Vogel V
Int J Pharm; 2011 Jul; 414(1-2):225-32. PubMed ID: 21571055
[TBL] [Abstract][Full Text] [Related]
10. Desolvation process and surface characteristics of HSA-nanoparticles.
Weber C; Kreuter J; Langer K
Int J Pharm; 2000 Mar; 196(2):197-200. PubMed ID: 10699717
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles.
Lin W; Garnett MC; Davis SS; Schacht E; Ferruti P; Illum L
J Control Release; 2001 Mar; 71(1):117-26. PubMed ID: 11245913
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity.
Kim TH; Jiang HH; Youn YS; Park CW; Tak KK; Lee S; Kim H; Jon S; Chen X; Lee KC
Int J Pharm; 2011 Jan; 403(1-2):285-91. PubMed ID: 21035530
[TBL] [Abstract][Full Text] [Related]
13. Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties.
Wacker M; Chen K; Preuss A; Possemeyer K; Roeder B; Langer K
Int J Pharm; 2010 Jun; 393(1-2):253-62. PubMed ID: 20417701
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles.
Avachat AM; Oswal YM; Gujar KN; Shah RD
Curr Drug Deliv; 2014; 11(3):359-70. PubMed ID: 24893995
[TBL] [Abstract][Full Text] [Related]
15. Optimization of the preparation process for human serum albumin (HSA) nanoparticles.
Langer K; Balthasar S; Vogel V; Dinauer N; von Briesen H; Schubert D
Int J Pharm; 2003 May; 257(1-2):169-80. PubMed ID: 12711172
[TBL] [Abstract][Full Text] [Related]
16. PEGylation of human serum albumin: reaction of PEG-phenyl-isothiocyanate with protein.
Meng F; Manjula BN; Smith PK; Acharya SA
Bioconjug Chem; 2008 Jul; 19(7):1352-60. PubMed ID: 18572961
[TBL] [Abstract][Full Text] [Related]
17. Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology.
Kouchakzadeh H; Shojaosadati SA; Maghsoudi A; Vasheghani Farahani E
AAPS PharmSciTech; 2010 Sep; 11(3):1206-11. PubMed ID: 20680708
[TBL] [Abstract][Full Text] [Related]
18. Polyethylene glycol improves conjugation of bovine hemoglobin and human serum albumin in a controlled ratio.
Zheng C; Bi J; Ma G; Su Z
Artif Cells Blood Substit Immobil Biotechnol; 2007; 35(6):568-84. PubMed ID: 18097785
[TBL] [Abstract][Full Text] [Related]
19. Desolvation process and surface characterisation of protein nanoparticles.
Weber C; Coester C; Kreuter J; Langer K
Int J Pharm; 2000 Jan; 194(1):91-102. PubMed ID: 10601688
[TBL] [Abstract][Full Text] [Related]
20. Colloidal dispersions of monodisperse magnetite nanoparticles modified with poly(ethylene glycol).
Barrera C; Herrera AP; Rinaldi C
J Colloid Interface Sci; 2009 Jan; 329(1):107-13. PubMed ID: 18930466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
